Newscast – Page 162 – media

InflaRx announces a $ 55M Series D financing and investment round

InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced a $ 55M Series D financing and investment round.
- Source: inflarx.de
- 594
- October 17, 2017
Market Views Series therapeutics
Warp Drive Bio Forms Strategic Collaboration to Advance Novel Classes of Antibiotics

Warp Drive Bio, Inc., a drug discovery company developing therapeutics that exploit the molecules and mechanisms of nature, announced today that it has formed a strategic collaboration with Roche to discover and develop multiple novel classes of antibiotics. The serious global health threat of multi-drug-resistant bacterial infections has created an urgent need for new antibiotics with novel structures and mechanisms of action.
- Source: Businesswire
- 436
- October 17, 2017
antibiotics infections Market Views
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC), including those who were heavily pretreated.
- Source: Pfizer
- 702
- October 17, 2017
Clinical Trials inhibitor Phase tyrosine kinase
NICE flip-flops to back Bristol’s Opdivo in head and neck cancer despite data ‘uncertainties’

Back in April, England’s cost watchdogs said they wouldn’t cover Bristol-Myers Squibb’s Opdivo in head and neck cancer due to “uncertain” clinical evidence. Now, though, they’re singing a different tune.
- Source: Fiercepharm
- 559
- October 16, 2017
New Approvals NHS Opdivo
Ebola vaccines from GSK, Merck elicit yearlong response, study finds

After initially setting out to test two vaccines on 28,000 volunteers during West Africa's deadly Ebola epidemic, a U.S.-Liberia research team had to dramatically reduce its aspirations when the outbreak started coming to an end. But the investigators have now published results showing the shots from GlaxoSmithKline and Merck elicited antibody responses that lasted one year after vaccination.
- Source: Fiercepharma
- 812
- October 16, 2017
aspirations Clinical Trials Ebola
University of Texas to develop cheap at-home test for heart failure

A research team at the University of Texas, US, is set to develop an affordable at-home diagnostic test for patients with heart failure.
- Source: medicaldevice-network
- 806
- October 16, 2017
diagnostic heart Researches
Ardelyx’s Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

Ardelyx, Inc. (ARDX) reported positive results from T3MPO-2, its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation (IBS-C). The study hit statistical significance for the primary endpoint and all secondary endpoints evaluated for the topline results and demonstrated the ability to normalize bowel movements.
- Source: finance.yahoo
- 564
- October 16, 2017
bowel syndrome Clinical Trials constipation
NIH accelerates the development of new cancer immunotherapy strategies for more patients

The National Institutes of Health(NIH) and 11 leading biopharmaceutical companies have launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.
- Source: nih.gov
- 559
- October 16, 2017
Market Views NIH PACT
Durable end to the HIV/AIDS pandemic likely will require an HIV vaccine

Despite remarkable gains in the treatment and prevention of HIV infection, development of an effective HIV vaccine likely will be necessary to achieve a durable end to the HIV/AIDS pandemic, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
- Source: Sciencedaily
- 575
- October 13, 2017
AIDS HIV Researches vaccine
Cholesterol byproduct hijacks immune cells, lets breast cancer spread

High cholesterol levels have been associated with breast cancer spreading to other sites in the body, but doctors and researchers don't know the cause for the link. A new study by University of Illinois researchers found that the culprit is a byproduct of cholesterol metabolism that acts on specific immune cells so that they facilitate the cancer's spread instead of stopping it.
- Source: Medicalxpres
- 729
- October 13, 2017
breast cancer cholesterol metabolism Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.